Ruxolitinib binding to human serum albumin: bioinformatics, biochemical and functional characterization in JAK2V617F(+) cell models

Ruxolitinib is a type I JAK inhibitor approved by FDA for targeted therapy of Philadelphia-negative myeloproliferative neoplasms (MPNs), all characterized by mutations activating the JAK2/STAT signaling pathway. Treatment with ruxolitinib improves constitutional symptoms and splenomegaly. However, p...

Descripción completa

Detalles Bibliográficos
Autores principales: De Marinis, Elisabetta, Ceccherelli, Alessia, Quattrocchi, Alberto, Leboffe, Loris, Polticelli, Fabio, Nervi, Clara, Ascenzi, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6841977/
https://www.ncbi.nlm.nih.gov/pubmed/31704999
http://dx.doi.org/10.1038/s41598-019-52852-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6841977/
https://www.ncbi.nlm.nih.gov/pubmed/31704999
http://dx.doi.org/10.1038/s41598-019-52852-9

Ejemplares similares